PMID- 34197635
OWN - NLM
STAT- MEDLINE
DCOM- 20210819
LR  - 20210819
IS  - 1537-2995 (Electronic)
IS  - 0041-1132 (Linking)
VI  - 61
IP  - 8
DP  - 2021 Aug
TI  - Washing transplants with Sepax 2 reduces the incidence of side effects associated 
      with autologous transplantation and increases patients' comfort.
PG  - 2430-2438
LID - 10.1111/trf.16566 [doi]
AB  - BACKGROUND: High-dose chemotherapy followed by autologous hematopoietic stem cell 
      transplantation (ASCT) is routinely used in various hematologic malignancies. 
      However, dimethylsulfoxide contained in cryopreserved grafts can cause adverse 
      events (AEs). STUDY DESIGN AND METHODS: Forty-three ASCTs were performed with 
      Sepax 2 washed grafts between 7/2016 and 10/2019. The aim of this study was to 
      determine whether washing out dimethyl sulfoxide (DMSO) from transplants using 
      the Sepax 2 (S-100) device is safe and reduces the incidence of DMSO-associated 
      AEs. RESULTS: The washing procedure was automated and that resulted in the 
      satisfactory recovery of total nucleated cells, CD34(+) cells, and colony forming 
      units of granulocyte and macrophages (85%, 80%, and 84%, medians). Time to 
      engraftment of leukocytes, granulocytes, and platelets as well as the number of 
      neutropenic days did not differ when compared to 20 consecutive ASCTs without 
      washing. The AE occurrence was lower compared to unwashed grafts: 81% versus 78% 
      during and shortly after grafts administration, 76% versus 69% in the following 
      day. CONCLUSION: We conclude that the washing of cryopreserved transplants using 
      Sepax 2 was feasible with a high recovery of hematopoietic cells, did not 
      influence time to engraftment, and resulted in the satisfactory reduction of AEs 
      and improved tolerance of the procedure.
CI  - (c) 2021 AABB.
FAU - Huvarova, Lucie
AU  - Huvarova L
AUID- ORCID: 0000-0003-1000-9378
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
AD  - Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
FAU - Koristek, Zdenek
AU  - Koristek Z
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
AD  - Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
FAU - Jelinek, Tomas
AU  - Jelinek T
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
AD  - Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
AD  - Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
FAU - Cerna, Lucie
AU  - Cerna L
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
FAU - Smejkalova, Jana
AU  - Smejkalova J
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
FAU - Navratil, Milan
AU  - Navratil M
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
AD  - Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
FAU - Grebenicek, Lukas
AU  - Grebenicek L
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
FAU - Tvrda, Ivana
AU  - Tvrda I
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
FAU - Michalikova, Magda
AU  - Michalikova M
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
FAU - Hajek, Roman
AU  - Hajek R
AD  - Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech 
      Republic.
AD  - Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
LA  - eng
GR  - CZ.02.1.01/0.0/0.0/16_019/0000868/European Regional Development Fund/
GR  - SGS03/European Regional Development Fund/
GR  - MH CZ - DRO - FNOs/2020/
GR  - SGS03/PrF/2019-2020/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210701
PL  - United States
TA  - Transfusion
JT  - Transfusion
JID - 0417360
RN  - 0 (Cryoprotective Agents)
RN  - YOW8V9698H (Dimethyl Sulfoxide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cryopreservation/instrumentation/methods
MH  - Cryoprotective Agents/*adverse effects/isolation & purification
MH  - Dimethyl Sulfoxide/*adverse effects/isolation & purification
MH  - Female
MH  - Hematopoietic Stem Cell Transplantation
MH  - Hematopoietic Stem Cells/cytology/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - DMSO
OT  - Sepax 2
OT  - autologous stem cell transplantation
OT  - hematopoietic cells
EDAT- 2021/07/02 06:00
MHDA- 2021/08/20 06:00
CRDT- 2021/07/01 17:28
PHST- 2021/05/08 00:00 [revised]
PHST- 2021/02/17 00:00 [received]
PHST- 2021/05/17 00:00 [accepted]
PHST- 2021/07/02 06:00 [pubmed]
PHST- 2021/08/20 06:00 [medline]
PHST- 2021/07/01 17:28 [entrez]
AID - 10.1111/trf.16566 [doi]
PST - ppublish
SO  - Transfusion. 2021 Aug;61(8):2430-2438. doi: 10.1111/trf.16566. Epub 2021 Jul 1.